Metformin: The Neuron’s Mitochondrial Guardian After Brain Injury

Traumatic brain injury (TBI) continues to be a significant contributor to mortality and persistent neurological deficits globally, yet efficacious interventions for secondary injury remain elusive. A substantial portion of the progressive tissue damage stems not solely from the initial impact, but also from enduring oxidative stress, compromised mitochondrial function, and amplified inflammatory signaling cascades. Within this pathophysiological landscape, the NLRP3 inflammasome has emerged as a pivotal instigator of neuronal harm, capable of precipitating pyroptosis, a particularly pro-inflammatory mode of programmed cellular demise. Concurrently, metformin has demonstrated considerable anti-inflammatory and neuroprotective capacities across a spectrum of neurological conditions. Given these complexities, a thorough investigation into the interplay between mitochondrial impairment and inflammasome activation in the aftermath of TBI is critically warranted.

Researchers affiliated with Xuanwu Hospital of Capital Medical University, Tianjin Medical University General Hospital, and the People’s Hospital of Honghuagang District of Zunyi published their findings on January 28, 2026, in the journal *Burns & Trauma* (DOI: 10.1093/burnst/tkag011). Their investigation revealed that metformin conferred neuroprotection subsequent to TBI by reinstating Mfn1-dependent mitochondrial dynamics, attenuating NLRP3 inflammasome activation, and diminishing pyroptotic cell death.

The research cohort initially demonstrated a marked upregulation of NLRP3, caspase-1, ASC, IL-1β, IL-18, and GSDMD within the lesioned brain following TBI. Furthermore, elevated levels of NLRP3, ASC, and GSDMD were observed in neuronal cells, indicative of robust inflammasome engagement and pyroptosis in these cells. Simultaneously, the injury profoundly dysregulated mitochondrial equilibrium, characterized by a reduction in Mfn1, a critical fusion protein, and an increase in phosphorylated Drp1, a promoter of fission. These alterations were correlated with mitochondrial fragmentation, diminished membrane potential, and heightened mitochondrial production of reactive oxygen species. Administration of metformin largely ameliorated these detrimental changes, as evidenced by the restoration of mitochondrial homeostasis, a decrease in inflammasome-associated proteins, and a reduction in neuronal pyroptosis in both in vivo and in vitro experimental models. The salutary effects were further corroborated by improvements in behavioral outcomes, with treated murine subjects exhibiting enhanced neurological assessments, superior motor control, augmented spatial memory, and reduced manifestations of anxiety- and depression-like behaviors. Mechanistic investigations provided deeper insight: the suppression of Mfn1 largely abrogated metformin’s capacity to preserve mitochondrial integrity and inhibit inflammasome activation, underscoring Mfn1’s indispensable role in mediating these protective effects. The investigators additionally ascertained that metformin’s regulation of Mfn1 was contingent upon AMPK signaling, rather than mTOR inhibition.

In the assessment of the study’s authors, their work illuminates Mfn1 as a crucial molecular nexus connecting mitochondrial stability and the NLRP3 inflammasome. Rather than merely mitigating inflammation downstream of the damage cascade, metformin appears to exert its influence at an earlier stage by safeguarding mitochondrial integrity and preempting the release of danger signals that instigate inflammasome activation. This realization imbues the findings with heightened significance, suggesting a more foundational strategy for protecting vulnerable neural populations subsequent to cerebral trauma.

The broader implications of this research extend beyond the therapeutic potential of a single repurposed agent. Given metformin’s widespread clinical utilization and well-established safety profile, it may present a more expeditious pathway toward clinical application compared to the development of entirely novel therapeutics. More comprehensively, these findings position mitochondrial dynamics at the forefront of future TBI research endeavors. Should these observations be substantiated through further preclinical and clinical scrutiny, interventions targeting the AMPK-Mfn1 pathway could prove instrumental in mitigating secondary brain injury, preserving neuronal viability, and improving long-term recovery trajectories following TBI.